Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells (Q43760313)

26 November 2017

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells (English)

1 reference

26 November 2017

0 references

4

1 reference

26 November 2017

W E Carson

1

1 reference

26 November 2017

R Parihar

2

1 reference

26 November 2017

M J Lindemann

3

1 reference

26 November 2017

J Dierksheide

5

1 reference

26 November 2017

N J Meropol

6

1 reference

26 November 2017

J Baselga

7

1 reference

26 November 2017

M A Caligiuri

8

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

European Journal of Immunology

26 November 2017

1 reference

26 November 2017

31

1 reference

26 November 2017

10

1 reference

26 November 2017

3016-3025

1 reference

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

26 November 2017

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Human inhibitory and activating Ig-like receptors which modulate the function of myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Interferon-gamma-induced increased sensitivity of HER2/neu-overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

An Fc gamma RIII (CD16)-specific autoantibody from a patient with progressive systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Analysis of perforin expression in human peripheral blood lymphocytes, CD56+ natural killer cell subsets and its induction by interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

ERBB2 oncogene in human breast cancer and its clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Synergistic anti-tumor effects with co-expression of GM-CSF and IFN-gamma in murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4141%282001010%2931%3A10%3C3016%3A%3AAID-IMMU3016%3E3.0.CO%3B2-J

10.1002/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO;2-J

21 January 2018

Identifiers

DOI

1 reference

release_cumnu2wghfadll667jzpgzulo4

26 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cumnu2wghfadll667jzpgzulo4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference